VBLT News and Press, Vascular Biogenics Ltd. From 06/15/21

koto_feja/E+ via Getty Images Vascular Biogenics (VBLT), operating as VBL Therapeutics has paused the recruitment of new patients in the U.S. for its ongoing OVAL Phase 3 study designed to investigate ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer...

TEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was notified by the U.S Foo...

VBL Therapeutics recently announced that they were allowed to add progression-free survival as a second primary endpoint for VB-111's Phase III OVAL study in ovarian cancer. The addition of the PFS endpoint could reduce VB-111's regulatory timeline by one year. Thus, moving VBL closer...

VBL Therapeutics (VBLT) has added ~8.0% in the pre-market after announcing an amendment to its OVAL study, a phase 3 randomized pivotal trial evaluating the combination of VB-111 and paclitaxel against placebo plus paclitaxel, in patients with platinum-resistant ovarian cancer....

Second primary endpoint added following discussion with the U.S. Food and Drug Administration Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for potential full FDA approval ...

TEL AVIV, Israel, May 20, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced that a poster providing an update on the OVAL Phase 3 registration enabling clinical trial of VB-111 in ovarian cancer will be presented at the American Society of Clinical Oncology (ASCO) Ann...

Stealth BioTherapeutics (MITO) +31% on Q1 results.Ultralife Corporation (ULBI) +22% on new contract from U.S. Army.China HGS Real Estate Inc. (HGSH) +14% on Q2 results.XpresSpa Group (XSPA) +9% on Q1 results.Reliance Global Group (RELI) +8%.Express (EXPR) +7%.Eloxx Pharmac...

Vascular Biogenics Ltd. (VBLT) Q1 2021 Earnings Conference Call May 11, 2021 8:30 AM ET Company Participants Lee Roth – Investor Relations Dror Harats – Chief Executive Officer Amos Ron – Chief Financial Officer Conference Call Participants Kevin DeGeeter – Oppenhe...

Conference Call and Webcast at 8:30 a.m. EDT Today OVAL Phase 3 registration-enabling study investigating VB-111 in patients with platinum-resistant ovarian cancer remains on track in spite of COVID-19, with over 260 patients enrolled; next DSMC review expected 3Q21 Cl...

TEL AVIV, Israel, May 04, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its first quarter financial results for the period ended March 31, 2021 on Tuesday, May 11, 2021 before market open. Professor Dror Harats, M.D, Chief Executive Officer and Amos Ron, Chief Financ...